



Chronic Liver Disease and Hepatocellular Carcinoma Biomarkers

Guest Editor:

Dr. Filippo Oliveri

Hepatology Unit, University
Hospital of Pisa, via Paradisa n. 2,
Pisa, Italy

Deadline for manuscript
submissions:

closed (31 December 2022)

Message from the Guest Editor

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer death worldwide. HCC arises mainly in patients with chronic liver diseases, and cirrhosis represents the major risk condition for its development.

Advanced HCC treatment is rapidly evolving, and in recent years, the availability of molecular targeted drugs is promoting the preselection of patients using drug-specific predictive biomarkers. Response to locoregional treatments and systemic therapies can currently be monitored simply using digital imaging and, thus, the AI-driven physics and mathematical models of the kinetics of different biomarkers may represent a new challenge for the amelioration of clinical monitoring and therapy individualization.

The aim of this Special Issue is to present original contributions and updated reviews on HCC biomarkers as provided by genomics, epigenomics, transcriptomics, proteomics, and other omics platforms which propose and discuss new or optimized tools for surveillance, early diagnosis, and individualization of the clinical management and treatment of HCC.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)